Back to Portfolio
M7U

Nynomic AG

€18.9 2026-04-15
Nynomic AG M7U BUFFETT / MUNGER / KLARMAN SUMMARY
1 SNAPSHOT
Price€18.9
2 BUSINESS

Nynomic AG is a German photonics roll-up with genuine technology assets in miniaturized spectroscopy, optical sensors, and measurement systems, but it fails the quality test for a Buffett-style investment. Peak ROE of 12% never exceeded cost of equity convincingly, the narrow moat is based on customer stickiness rather than pricing power, and the 12-company roll-up model adds complexity without proven synergies. The stock has already rallied 130% from its 2025 low, pricing in significant recovery at 1.3x book and 16x normalized mid-cycle earnings. For a C+/B- quality business with high cyclicality and small-cap illiquidity, this offers insufficient margin of safety. Wait for a pullback to EUR 12-13 (0.9x book) where the strong balance sheet (74% equity ratio, minimal net debt) provides adequate downside protection, or EUR 9-10 (near tangible book) for genuine deep value. Monitor Q1/Q2 2026 results for evidence that Q4 2025's 12.6% EBIT margin is sustainable, not a one-quarter anomaly.

3 MOAT NARROW

Installed base switching costs (optical sensors embedded in production lines require recalibration/revalidation to replace), niche specialization across 12 subsidiaries in miniaturized spectroscopy, MEMS sensors, and in-situ metrology. Full-line one-stop-shop positioning unique but not irreplaceable.

4 MANAGEMENT
CEO: Maik Muller (Technology/Operations) and Fabian Peters (co-Management Board)

Average-to-Poor - Acquisitions have not delivered returns above cost of capital (peak ROIC ~8.5%). NyFIT2025 restructuring suggests earlier integration was incomplete. No dividends or buybacks despite years of profitability.

5 ECONOMICS
2.2% Op Margin
-0.5% ROIC
-0.6% ROE
-18.7x P/E
6 VALUATION
FCF Yield0%
DCF Range14 - 20

At upper end of base-case fair value range (EUR 16-20). 130% rally from 52-week low already prices in significant recovery.

7 MUNGER INVERSION
Kill Event Severity P() E[Loss]
Cyclical trough with 22% revenue decline from peak and collapse to 2% EBIT margin. Recovery timing uncertain. HIGH - -
EUR 43.3M goodwill (44% of equity) at impairment risk if trough persists. 12-company roll-up complexity may destroy rather than create value. MED - -
8 KLARMAN LENS
Downside Case

Cyclical trough with 22% revenue decline from peak and collapse to 2% EBIT margin. Recovery timing uncertain.

Why Market Right

Prolonged German/European industrial recession; Goodwill impairment if subsidiaries continue underperforming; Cash depletion below EUR 10M constraining M&A optionality; Management credibility gap (2024 guidance was cut mid-year); US tariff escalation affecting export demand

Catalysts

NyFIT2025 restructuring delivering EUR 5-6M annualized savings from 2026; Q4 2025 EBIT margin of 12.6% signals operational recovery; Secular demand for spectroscopy in pharma (PAT/QbD), semiconductors, and sustainability; Management EUR 200M revenue / 16-19% EBIT margin medium-term target; NLIR mid-infrared technology could open new addressable markets; Potential acquisition target for larger photonics player (Halma, Spectris, Bruker)

9 VERDICT WAIT
C+ Quality Moderate-Strong balance sheet (74% equity ratio, minimal net debt) offset by EUR 43.3M goodwill (44% of equity), declining cash position (EUR 10.4M, down from EUR 26.8M in 2021), and negligible/negative FCF. No bankruptcy risk but no fortress either.
Strong Buy€9.5
Buy€13
Fair Value€20

Do not initiate. Monitor Q1/Q2 2026 results for recovery confirmation. Set price alert at EUR 13.00 (Accumulate) and EUR 9.50 (Strong Buy).

🧠 ULTRATHINK Deep Philosophical Analysis

Nynomic AG -- Ultrathink: A Philosophical Deep-Dive

"It is far better to buy a wonderful company at a fair price than a fair company at a wonderful price." -- Warren Buffett

The Core Question: Is This a Hidden Champion or a Hidden Trap?

The narrative around Nynomic is seductive. A German "Mittelstand" photonics company, assembling a portfolio of specialized optical measurement businesses, each a niche leader in its own right. Miniaturized spectrometers. MEMS-based sensors. In-situ semiconductor metrology. The language of the annual report drips with the vocabulary of innovation -- "AI integration," "cloud-based solutions," "sustainability-driven measurement technology." The company even has a restructuring program with a catchy name: NyFIT2025.

But Buffett's first question is never "What does it do?" His first question is: "What are its economics?" And the economics of Nynomic, stripped of the innovation narrative, are sobering.

In the best year of its corporate life -- 2023, after a decade of acquisitions and organic growth -- Nynomic earned a return on equity of 8.9%. This is not the 20-30% ROE of a true compounder. This is barely above the cost of equity for a German small-cap. It means that every euro of shareholder capital deployed in this business has, even under optimal conditions, barely earned its keep.

Munger would put it more bluntly: "If the business earns 8% on equity and you hold it for a long time, you are going to get 8% on your money -- no matter what you paid for it." And 8% is not what we are looking for.

The reason the economics are mediocre is structural, not cyclical. Nynomic is a roll-up. It has acquired 12 companies over the past decade, paying meaningful premiums for each (hence EUR 43.3M in goodwill on EUR 98M of equity). Each acquisition dilutes returns on capital because the purchase price exceeds the tangible assets acquired. The only way a roll-up creates genuine value is if the combined platform earns significantly more than the sum of its parts -- through cross-selling, shared R&D, procurement leverage, or operational synergies. The evidence at Nynomic suggests these synergies are elusive. If they had materialized, we would see expanding margins and rising ROIC. Instead, we see the opposite: margins peaked at 13% and have been declining, and the company just launched a restructuring program to cut costs -- an implicit admission that the platform had grown bloated.

Moat Meditation: The Difference Between Stickiness and Pricing Power

There is a meaningful distinction in competitive analysis between customer stickiness and genuine pricing power. Nynomic has the former but not the latter.

When Nynomic installs an optical sensor in a pharmaceutical production line or a semiconductor fab, the customer faces real switching costs. Recalibration takes time. Revalidation requires regulatory approval in some cases. Process engineers are familiar with the Nynomic interface and would need retraining. These are real frictions, and they keep customers in place for the current equipment lifecycle -- typically 5-10 years.

But this is not the same as pricing power. Pricing power means you can raise prices faster than costs, year after year, without losing customers. Coca-Cola has pricing power. Visa has pricing power. Nynomic does not. When Nynomic's customers build a new production line, they shop around. They get quotes from Hamamatsu, from Ocean Insight, from Bruker. The Nynomic sensor on the old line does not guarantee the Nynomic sensor on the new line.

The evidence confirms this. Gross margins peaked at 29.4% in 2023 and declined to approximately 19% in 2025. This is not the behavior of a business with pricing power. A company with genuine pricing power would maintain or expand margins through a downturn, because it could hold prices while competitors scramble. Nynomic's collapsing margins suggest it is a price-taker, not a price-maker, in its end markets.

Munger's framework for moats identifies five sources: brand, network effects, switching costs, cost advantages, and regulatory barriers. Nynomic has a mild version of switching costs and nothing else. No brand premium (it is a B2B component supplier). No network effects (optical sensors are not platforms). No cost advantages (German labor costs are among the highest in the world, and personnel is 42% of revenue). No regulatory barriers (anyone can make a spectrometer).

The moat exists. But it is narrow, shallow, and not widening.

The Owner's Mindset: Would Buffett Own This for 20 Years?

Absolutely not. Let me count the disqualifying factors:

First, the returns on capital are inadequate. Buffett requires 15%+ ROE sustained over decades. Nynomic has never achieved 12%, even at peak.

Second, the business model is inherently acquisitive. Buffett distrusts serial acquirers because they tend to overpay in good times (when targets are expensive and management is optimistic) and write down in bad times (when the acquisitions underperform). Nynomic is following this exact playbook. The goodwill-to-equity ratio of 44% is the financial fingerprint of an acquirer who paid premiums that have not been justified by subsequent performance.

Third, the cyclicality is severe. Revenue swings of 20%+ and EBIT swings of 80%+ make this business nearly impossible to value with confidence. Buffett wants businesses whose earnings he can predict with reasonable accuracy five years out. With Nynomic, he cannot predict with accuracy five months out.

Fourth, there is no return of capital to shareholders. No dividends since at least 2007. No buybacks. All cash flow is reinvested in the business or used for acquisitions. When a business earns mediocre returns on capital and reinvests everything, shareholders get the worst of all worlds: below-market returns on a growing capital base, with no cash to redeploy elsewhere.

Fifth, the governance is opaque. For a publicly traded company, the inability to easily determine shareholder structure, insider ownership, or management compensation from IR materials is a red flag. Transparency is the minimum standard, not a bonus feature.

Risk Inversion: What Could Destroy This Business?

Inverting the analysis reveals several paths to permanent value destruction:

Scenario A: Death by Goodwill. If the trough persists through 2027 and two or three subsidiaries significantly underperform, auditors could require a goodwill impairment of EUR 15-20M. This would wipe out 15-20% of equity, push the equity ratio below 60%, and potentially trigger debt covenants. The stock, already down 65% from ATH, could revisit its EUR 8 low or worse.

Scenario B: Technology Leapfrog. A larger player (Hamamatsu, ams-OSRAM) develops a next-generation miniaturized sensor platform that is cheaper, more accurate, and more easily integrated. Nynomic's switching costs evaporate as customers adopt the superior technology on new production lines. Revenue declines accelerate. The roll-up unravels as individual subsidiaries lose relevance.

Scenario C: Cash Exhaustion. Cash has declined from EUR 26.8M (2021) to EUR 10.4M (H1 2025). If operating cash flow does not recover and the company continues investing at current levels, cash could approach zero by end-2026. This would force either debt issuance (increasing leverage on a weak income statement) or equity dilution (destroying per-share value for existing shareholders).

None of these scenarios is probable in isolation, but none is implausible either. The probability of at least one occurring is meaningful -- perhaps 20-30%.

Valuation Philosophy: What Is the Right Price for Mediocrity?

Here is where the analysis becomes interesting. Nynomic is not a good business. But is it a good investment?

The answer depends entirely on price. Klarman's first principle: the most important thing in investing is price. The second most important thing is also price. The third is -- you guessed it -- price.

At EUR 18.90 (1.32x book, 16x normalized earnings), the answer is no. This price implies mid-cycle operations resume, margins recover to 11-12%, and the company earns its way back to EUR 1.10-1.20 EPS. All of these things are possible but far from certain. Paying 16x for an uncertain recovery in a C+ quality business with a narrow moat offers no margin of safety.

At EUR 13.00 (0.9x book, 11x normalized), the answer becomes more interesting. Here you are paying less than book value for a company with a 74% equity ratio and minimal net debt. The balance sheet provides downside protection. If recovery comes, the upside is 30-50%. If it does not, the assets have enough value to limit permanent loss of capital.

At EUR 9.50 (0.66x book, 8x normalized, near tangible book value), the answer approaches yes. At this price, you are essentially getting the technology assets, customer relationships, and operating businesses for free after accounting for tangible book value. The goodwill becomes a free option on the roll-up thesis working. Even in the bear case, liquidation value provides support.

The discipline is in the waiting. The stock has rallied 130% from its low. The temptation is to chase the recovery. But chasing recoveries in mediocre businesses is how permanent capital loss happens. Either the recovery confirms itself over 2-3 quarters (and you buy at a slightly higher but validated price), or the stock revisits lower levels (and you buy with genuine margin of safety). Either way, patience is rewarded.

The Patient Investor's Path

The action plan is clear:

Now (EUR 18.90): Do nothing. The risk/reward is unfavorable. Set price alerts at EUR 13.00 and EUR 9.50.

At EUR 13.00 (Accumulate): Initiate a 1-2% position. The balance sheet protects against catastrophic loss. The recovery thesis has time to prove itself.

At EUR 9.50 (Strong Buy): Size up to 2-3% maximum. This is deep value territory with a margin of safety adequate for the risk profile.

Monitor: Q1/Q2 2026 results (does Q4 2025's 12.6% EBIT margin sustain?). Order backlog (needs to stabilize above EUR 45M). Cash position (decline below EUR 8M is a warning sign). Goodwill impairment tests in the 2025 annual report.

If recovery confirms by mid-2026: Reassess. If the stock has not risen significantly and margins are proving sustainable at 10%+, the quality grade improves to B- and the risk/reward shifts favorably.

The opportunity in Nynomic is not in the business itself -- it is in the potential mispricing of a cyclical trough. And mispricing opportunities require patience, not conviction in the underlying business.

As Klarman writes: "Value investing is at its core the marriage of a contrarian streak and a calculator." The calculator says wait. The contrarian streak says the time to buy a German photonics roll-up is not when it has rallied 130% from its low, but when nobody wants it at all.

"The stock market is a device for transferring money from the impatient to the patient." -- Warren Buffett

Executive Summary

Nynomic AG is a German photonics group that manufactures non-contact optical measurement systems across three segments: Clean Tech (67% of revenue), Green Tech (20%), and Life Science (13%). The company is a roll-up of 12 subsidiaries including Avantes, tec5, LayTec, Spectral Engines, and others, assembled through a buy-and-build strategy since the mid-2010s. It is positioned as a "one-stop shop" for spectroscopy and optical sensor solutions, from components through systems to software/cloud integration.

The company is currently navigating its deepest cyclical trough in a decade. Revenue fell from a peak of EUR 118M (2023) to EUR 92.6M (2025), with EBIT collapsing from EUR 15.4M to EUR 2.0M. A restructuring program (NyFIT2025) is underway with EUR 5-6M in annualized savings expected from 2026. Q4 2025 showed early recovery (12.6% EBIT margin, EUR 27.7M revenue), and management guides EUR 100-105M revenue with 6-8% EBIT margin for 2026.

Verdict: WAIT -- Interesting turnaround candidate but too many unresolved risks. Accumulate at EUR 12-13 (0.85x book) on proven recovery. Strong Buy at EUR 9-10 (0.65x book) in panic scenario.

Phase 1: Risk Assessment

1.1 Small-Cap Liquidity Risk (HIGH)

  • Market cap EUR ~124M. Thinly traded on XETRA with limited institutional coverage (Montega, NuWays only).
  • Beta of 0.67 understates true risk -- the stock collapsed from EUR 54.60 (2021 ATH) to EUR 8.22 (2025 low), an 85% peak-to-trough drawdown.
  • Position sizing must account for illiquidity. A 2-3% portfolio position is maximum prudent allocation.

1.2 Cyclical Revenue Dependence (HIGH)

  • Revenue declined 22% from peak (EUR 118M to EUR 92.6M) over just two years.
  • Customer order hesitancy in industrial spectroscopy is pronounced. Order backlog fell from EUR 53.9M (end-2023) to EUR 45.0M (end-2025), a 17% decline.
  • Clean Tech segment (semiconductors, environmental monitoring) is the largest at 67% of revenue and most cyclically exposed.
  • Management cited "reluctance to make binding short- and medium-term product call-offs" -- this suggests customers are not just delaying but potentially reconsidering capex plans entirely.

1.3 Acquisition Integration Risk (MODERATE-HIGH)

  • Nynomic is a roll-up of 12 companies. Goodwill is EUR 43.3M -- approximately 33% of total assets and 44% of shareholder equity.
  • Goodwill-to-equity ratio of 44% is elevated and indicates significant acquisition premium risk if subsidiaries underperform.
  • The company has already written down value (net income was negative EUR 0.64M in 2024 and negative EUR 6.65M TTM despite positive EBIT, suggesting impairments/write-downs).
  • Further impairments are possible if the trough persists beyond 2026.

1.4 German Industrial Slowdown (MODERATE)

  • German manufacturing PMI has been contractionary for most of 2024-2025.
  • Nynomic's customers are predominantly European industrials in semiconductor, pharma, and agriculture -- all facing varying degrees of cyclical headwinds.
  • US tariff exposure cited at EUR 0.5M impact in 2025 -- small but indicative of global trade friction effects.

1.5 Competition from Larger Players (MODERATE)

  • Hamamatsu Photonics (JPY 1T+ market cap), Ocean Insight (Halma subsidiary), Bruker, Zeiss, ams-OSRAM, and Si-Ware Systems all compete in adjacent or overlapping segments.
  • Avantes (Nynomic subsidiary) competes directly with Ocean Insight in miniaturized spectrometers.
  • Nynomic's advantage is integration (full stack from components to software), but larger players have superior R&D budgets and distribution.

1.6 Management/Governance Opacity (MODERATE)

  • Shareholder structure is not transparently disclosed on IR site.
  • No dividends paid since at least 2007 despite years of profitability.
  • Insider ownership details are difficult to verify from public sources.
  • Two-person management board (Maik Muller, Fabian Peters) with limited public communication cadence.

1.7 Restructuring Execution Risk (MODERATE)

  • NyFIT2025 targets EUR 5-6M annualized savings but cost EUR 1.5M+ in one-time charges.
  • Restructuring included intra-group merger of Spectral Engines into m-u-t GmbH -- organizational simplification but potential disruption.
  • Q4 2025 showed promising results (12.6% EBIT margin) but one quarter does not confirm a trend.

Phase 1 Conclusion: Risk is elevated across multiple dimensions. This is not a sleep-well-at-night investment. The cyclical trough, goodwill overhang, and small-cap illiquidity create a triple vulnerability. However, the balance sheet is solid (73.8% equity ratio) and provides buffer.

Phase 2: Financial Fortress Analysis

2.1 Income Statement (5-Year History)

Metric 2020 2021 2022 2023 2024 2025P
Revenue (EUR M) 78.8 105.1 116.8 118.0 102.4 92.6
EBIT (EUR M) 7.8 12.4 14.9 15.4 7.4 2.0
EBIT Margin 9.9% 11.8% 12.8% 13.1% 7.2% 2.2%
Net Income (EUR M) 4.4 7.9 7.5 9.3 -0.6 -6.7
EPS (EUR) 0.83 1.37 1.26 1.47 -0.10 -1.01
Gross Profit (EUR M) 20.0 27.0 31.5 34.7 23.8 ~18
Gross Margin 25.4% 25.7% 27.0% 29.4% 23.1% ~19%

Key Observations:

  • Revenue grew at ~15% CAGR from 2020-2023 (partly organic, partly acquisitive).
  • The gross margin peaked at 29.4% in 2023 and has been declining sharply -- this is concerning as it suggests pricing pressure or unfavorable mix shift, not just volume deleveraging.
  • EBIT margin of 13% was the peak (2023). Mid-cycle normalized margin is likely 10-12%.
  • Net income turned negative in 2024 and worsened in 2025 due to impairments/restructuring charges on top of operational weakness.

2.2 Balance Sheet

Metric 2020 2021 2022 2023 2024 H1 2025
Total Assets (EUR M) 103.0 120.3 138.5 151.5 139.5 131.0
Shareholders' Equity (EUR M) 51.0 66.5 77.0 103.9 103.0 98.1
Equity Ratio 49.5% 55.3% 55.6% 68.6% 73.8% 74.9%
Cash (EUR M) 22.1 26.8 26.6 21.9 16.3 10.4
Total Debt (EUR M) 39.4 34.4 31.6 24.9 19.0 17.4
Net Debt (EUR M) 17.3 7.6 5.0 3.0 2.6 7.0
Goodwill (EUR M) 34.0 40.6 44.7 44.7 43.3 43.3
Book Value/Share (EUR) 8.45 10.57 11.91 15.08 14.88 14.33

Key Observations:

  • The balance sheet is genuinely strong. Equity ratio of 74% is conservative for a German industrial company.
  • Net debt is minimal at EUR 7M (H1 2025). Interest coverage is not a concern.
  • However, goodwill of EUR 43.3M represents 44% of equity -- a significant impairment risk if subsidiaries continue underperforming.
  • Cash has been declining (EUR 26.8M in 2021 to EUR 10.4M in H1 2025) as operating cash flow weakened and investments continued.
  • Tangible book value = EUR 98.1M - EUR 43.3M - EUR 4.6M = EUR 50.2M, or EUR 7.64/share. At EUR 18.90, the stock trades at 2.5x tangible book.

2.3 Cash Flow

Metric 2023 2024
Operating Cash Flow (EUR M) 3.2 7.8
Investments (EUR M) 13.0 9.7
Depreciation (EUR M) 4.8 5.1
Personnel Costs (EUR M) 40.2 42.7

Key Observations:

  • OCF improved in 2024 despite lower revenue (working capital release likely).
  • CapEx/investment levels (EUR 9.7M) exceed depreciation (EUR 5.1M), indicating continued reinvestment but also potential for cuts in a prolonged downturn.
  • Free cash flow has been negligible or negative in recent years when accounting for investments.
  • Personnel costs of EUR 42.7M represent 42% of revenue -- a very high labor intensity for a technology company, limiting operating leverage.

2.4 Return Metrics

Metric 2020 2021 2022 2023 2024
ROE 8.6% 11.9% 9.7% 8.9% -0.6%
ROIC (approx.) 5.5% 8.5% 8.0% 8.5% -0.5%

Key Observations:

  • ROE never exceeded 12% even in the best year. This is below Buffett's 15% threshold.
  • ROIC approximation (EBIT after tax / (equity + net debt)) suggests the business has never earned significantly above its cost of capital.
  • The acquisition-heavy model dilutes returns as goodwill inflates the capital base.
  • This is NOT a high-quality compounder. It is a mediocre-return roll-up that was growing into its valuation during the upcycle.

Phase 2 Conclusion: Balance sheet is a fortress (equity ratio 74%, minimal net debt). But the income statement reveals a business with structurally low margins (10-13% EBIT at peak), negative operating leverage in downturns, and returns on capital that never cleared the cost-of-capital hurdle convincingly. Quality grade: C+ to B-.

Phase 3: Moat Assessment

3.1 Moat Sources

a) Specialization / Niche Leadership (Narrow)

  • Nynomic positions itself as the only "full-line" optical measurement technology provider spanning components, systems, and software/cloud.
  • In sub-niches (e.g., in-situ LED/VCSEL metrology via LayTec, MEMS spectral sensors via Spectral Engines, fiber-optic spectrometers via Avantes), the company holds meaningful market positions.
  • However, each niche is small, and the aggregation of niche positions does not create a wide moat.

b) Switching Costs (Moderate)

  • Optical sensors embedded in production lines (semiconductor fabs, pharma manufacturing, food processing) create moderate switching costs once installed.
  • Recalibration, revalidation, and process requalification costs make customers reluctant to switch mid-cycle.
  • However, at contract renewal / new project decisions, Nynomic faces genuine competition from larger players with bigger R&D budgets.

c) Technology / IP (Narrow)

  • Spectral Engines' MEMS-based miniaturized spectrometers represent genuinely novel technology.
  • NLIR's mid-infrared spectroscopy conversion technology is innovative.
  • But in photonics, technology advantages are rarely durable -- Hamamatsu, ams-OSRAM, and others have vast R&D resources to replicate or leapfrog.

d) Roll-Up Integration (Questionable)

  • The bull case argues that combining 12 companies creates cross-selling and platform synergies.
  • The bear case argues that managing 12 entities across Germany, Finland, Netherlands, and Denmark creates coordination overhead that dilutes focus.
  • Evidence to date: the NyFIT2025 restructuring (merging entities, cutting costs) suggests the platform had not achieved meaningful synergies organically.

3.2 Moat Verdict

Narrow moat with durability risk. The individual niches are defensible for 5-7 years, but the aggregation does not create a wide moat. The business lacks pricing power (falling gross margins in a downturn), network effects, or irreplaceable assets. The moat is best described as "customer stickiness in installed base" -- real but not wide.

Phase 3 Conclusion: Moat is narrow and somewhat fragile. It protects against competition in existing installed base but does not provide pricing power.

Phase 4: Valuation and Synthesis

4.1 Current Valuation Metrics

Metric Value Context
Price EUR 18.90 +130% from 52-week low of EUR 8.22
Market Cap EUR 124M Small-cap
P/B 1.27x At book value
P/Tangible Book 2.47x Goodwill-adjusted
P/E (TTM) N/A Negative earnings
P/E (Forward, 2026E) ~105x Based on consensus
EV/EBITDA (mid-cycle) ~7-8x Using EUR 15M normalized EBITDA
EV/Revenue 1.3x On TTM revenue of EUR 92.6M
FCF Yield Negligible Negative FCF currently

4.2 Normalized Earnings Approach

Assuming recovery to mid-cycle levels (2021-2022 average):

  • Revenue: EUR 105-110M
  • EBIT margin: 11-12%
  • EBIT: EUR 11.5-13.0M
  • Net income (after 30% tax, minorities): EUR 7-8M
  • Normalized EPS: EUR 1.05-1.20

At EUR 18.90, the stock trades at 16-18x normalized mid-cycle earnings. This is not cheap for a business with:

  • Sub-12% ROE at peak
  • Cyclical revenue with 20%+ drawdowns
  • Narrow moat
  • Small-cap illiquidity premium required

4.3 Book Value / Asset-Based Valuation

  • Book value per share: EUR 14.33 (H1 2025)
  • Price/Book: 1.32x
  • Tangible book (ex-goodwill, ex-intangibles): EUR 7.64/share
  • Price/Tangible Book: 2.47x

For a roll-up with mediocre returns on capital, 1.3x book is not obviously cheap. A fair P/B for a 9% ROE business at a 9% cost of equity is approximately 1.0x book. At 12% ROE (peak), fair P/B is approximately 1.3x.

4.4 Comparable Transactions

German photonics/optical companies:

  • Jenoptik (JEN.DE): Trades at ~2.5x book, 18-20x P/E, but with wider moat and defense exposure.
  • Carl Zeiss Meditec (AFX.DE): Trades at ~3.5x book, premium moat.
  • Nynomic at 1.3x book is discounted relative to peers, reflecting lower quality and smaller scale.

4.5 DCF Scenario Analysis

Base Case (Recovery to mid-cycle by 2027):

  • 2026E revenue: EUR 103M, EBIT margin 7%, EBIT EUR 7.2M
  • 2027E revenue: EUR 115M, EBIT margin 11%, EBIT EUR 12.7M
  • 2028E+ revenue growth: 5-7% (organic + selective bolt-ons)
  • Terminal EBIT margin: 12%
  • WACC: 10% (small-cap premium)
  • Terminal growth: 2%
  • DCF Fair Value: EUR 16-20/share

Bull Case (NyFIT2025 fully delivers, medium-term target achieved):

  • Revenue reaches EUR 200M by 2030 (management target) with 16-19% EBIT margin
  • Requires significant acquisitions and/or organic acceleration
  • DCF Fair Value: EUR 30-40/share
  • Probability: 15-20% (requires near-perfect execution)

Bear Case (Prolonged trough, impairments):

  • Revenue stays below EUR 100M through 2027
  • Goodwill impairment of EUR 10-15M
  • Further equity dilution possible if acquisitions continue
  • DCF Fair Value: EUR 8-11/share
  • Probability: 25-30%

4.6 Entry Price Calculation

Level Price (EUR) P/B Rationale
Strong Buy 9.50 0.66x Below tangible book, panic scenario, bear case DCF support
Accumulate 13.00 0.91x Slight discount to book, recovery starting to prove out
Fair Value (base) 17.00 1.19x Mid-cycle DCF central estimate
Current 18.90 1.32x Above base-case fair value

4.7 Medium-Term Target

Management's EUR 200M revenue / 16-19% EBIT margin target is ambitious and requires:

  1. Doubling revenue from current levels (~8-10% CAGR over 5 years minimum)
  2. Significant margin expansion (from current 2% to 16-19%)
  3. Likely 2-3 more acquisitions

This target is aspirational, not bankable. If achieved, the stock would be significantly undervalued at current levels. But the probability-weighted expected value does not yet favor entry at EUR 18.90.

Investment Thesis

Bull Case

Nynomic is a German "hidden champion" in optical metrology, trading at 1.3x book at the deepest point of a cyclical trough. The NyFIT2025 restructuring is working (Q4 2025 EBIT margin of 12.6% proves it). Secular trends in sustainability (Green Tech), pharmaceutical quality control (Life Science), and semiconductor metrology (Clean Tech) provide long-term demand growth. The buy-and-build platform creates optionality. If management achieves even half of its EUR 200M target, the stock is significantly undervalued.

Bear Case

Nynomic is a mediocre-return roll-up that never earned above its cost of capital even in good times. The goodwill-heavy balance sheet masks true asset value. Twelve subsidiaries across four countries create management complexity that destroys rather than creates value. Larger competitors (Hamamatsu, Zeiss, Bruker) will eventually erode niche positions. The stock has already rallied 130% from lows and is no longer cheap at 1.3x book for a C+/B- quality business.

My Assessment

The bear case has more structural merit. Nynomic fails the Buffett quality test: ROE never exceeded 12%, the moat is narrow, and the business model (industrial roll-up) has a poor long-term track record across industries. The stock has already priced in significant recovery from its EUR 8.22 low. At EUR 18.90, the risk/reward is unfavorable -- too expensive for the quality on offer.

However, the business could become interesting at lower prices. At EUR 12-13 (0.85x book), you get a balance sheet with 74% equity ratio, minimal net debt, and real technology assets at a genuine discount. At EUR 9-10 (0.65x book, near tangible book), you get potential deep value with restructuring optionality.

Final Verdict

WAIT -- Nynomic is a mediocre-quality cyclical turnaround trading at a slight premium to base-case fair value. The stock has already repriced significantly from its 2025 lows. Wait for either (a) proven recovery over 2-3 quarters confirming mid-cycle margins, or (b) a pullback to EUR 12-13 where the margin of safety is adequate for the risk profile.

Price (EUR) P/B P/E (norm.)
Strong Buy 9.50 0.66x 8x
Accumulate 13.00 0.91x 11x
Current 18.90 1.32x 16x

Key Monitor Points:

  1. Q1/Q2 2026 results -- does the Q4 2025 margin recovery sustain?
  2. Order backlog trajectory -- needs to stabilize above EUR 45M
  3. Goodwill -- any further impairments would destroy equity cushion
  4. Cash position -- further decline below EUR 10M signals stress
  5. Management execution on NyFIT2025 savings realization

Analysis based on public filings, annual reports, and company IR materials. No analyst reports used as primary inputs. All valuations are author's independent estimates.

=== VERDICT: M7U | WAIT | SB:EUR 9.50 | Acc:EUR 13.00 | Current:EUR 18.90 ===